



## ***Professor Itamar Raz***

---

### **Personal Details:**

**Date of Birth:** June 9, 1948  
**Place of Birth:** Jerusalem, Israel  
**Family Status:** Married + 5

**Work Address:** Diabetes Unit, Hadassah Hebrew University Hospital  
PO Box 12000, Jerusalem, Israel 91120  
**Home Address:** 46 Uruguay Street, Jerusalem, Israel

**Work Phone:** (972) 2-6777535, 2-6778021  
**Work Fax:** (972) 2-6420597  
**Home Phone:** (972) 2-6428087  
**Mobile Phone:** (972) 50-7874066  
**E-mail:** [ntv502@netvision.net.il](mailto:ntv502@netvision.net.il)

### **Current Positions:**

- Professor of Medicine
- Head, Diabetes Unit, Hadassah Ein Kerem Hospital, Jerusalem Israel
- President, D-Cure Diabetes Care to Cure in Israel
- Head, Israel National Diabetes Council

### **Military Duty:**

1966 - 1969 Active Service, Captain, Infantry (Golani Brigade)  
1974 - 1997 Reserve duty, Major, Medical Corps

### **Education:**

Pharmacology - 1973 - Hebrew University, Hadassah School of Pharmacy, Jerusalem (BS)  
Medicine - 1981 – Hebrew University, Hadassah Medical School (MD)  
Internal Medicine - 1981 – Hadassah University Hospital (residency)

### **Academic Appointments:**

1985 - Lecturer in Medicine, Hebrew University - Hadassah Medical School, Jerusalem  
1988 - Senior Lecturer in Medicine, Hebrew University - Hadassah Medical School  
1995 - Associate Professor of Medicine, Hebrew University - Hadassah Medical School  
2003 - Professor of Medicine, Hebrew University – Hadassah Medical School

**Positions and Employment:**

1985	Lecturer, Hebrew University, Hadassah Hospital Acting Head, Diabetes Unit, Hadassah University Hospital Senior Physician, Internal Medicine Head, Hebrew University Student Health Service,
1988	Research Visiting Professor, NIH Center for Diabetes Research (NIDDK), Phoenix, Arizona (Sabbatical)
1989	Chief Physician, Internal Medicine, Hadassah University Hospital
1992	Chief Physician, Hebrew University, Hadassah Hospital
1992- Present	Head of Diabetic Clinics, Hadassah University Hospital
2001	Director, Hadassah Center for the Prevention of Diabetes and its Complications, Hadassah University Hospital
2001- Present	Head of Diabetes Unit, Hadassah University Hospital.

---

**National and International Associations:**

1990-1993	Secretary, Israel Society for Internal Medicine
1992- 2004	President, Israel Diabetes Association
1993-1998	Board of International Diabetes Federation, Europe
1999-	Director, Israel Diabetes Research Group
1999-	Director, Eastern and Central European, Mediterranean Diabetes Research Consortium
	Head, Israeli Medical Association Committee on National Clinical Research
1999-2001	Member, Scientific Board of UPDATE EUROPE (Austrian Society of Internal Medicine - diabetes policy formulation committee)
1999-2000	Head, Steering Committee, Eastern and Central European Guidelines for the Treatment of Diabetes
2000	Head, Committee on the development of guidelines for treatment of diabetes, Israeli Medical Association
2000-	Member, "Forum 2000," Israeli Medical Association Steering Committee
2002-	Chairman of Diabetes International Research and Education Cooperative Team (DIRECT)
2003-	European Country Representative to International Diabetes Federation (IDF)
2004-	President, D Cure – Diabetes Care to Cure in Israel, Non- profit Organization
2004-	Head, Israel National Diabetes Council

**Academic Committees:**

1990-1994	Member of the Hebrew University - Hadassah Senate
1990-1994	Member of Hadassah University Hospital Committee for Medical Equipment
1991-	Chief Organizer of Combined Renal - Pancreas Transplantation Committee, Hadassah Univ. Medical Center
1992-1995	Member of Committee for Exchange Programs
1994-2001	Member of Hadassah Pharmacy and Therapeutics Com.

2001- Member of Hadassah Committee for Excellence Centers

**Governmental Committees:**

1993-1998 Head, Israeli Ministry of Health Committee for Diabetic Health Care  
1993-1998 Head, Israeli Ministry of Health Committee for The Treatment of Diabetes and Atherosclerosis.  
1994-1996 Head, Israeli Ministry of Health Committee for Pancreas and Kidney Transplantation.  
1996-2000 Member, Ministry of Health Drug Committee.  
1997-1999 Head, Chief Scientist Committee for Diabetic Grants Evaluation  
1998- Head, Chief, Scientist Committee of National Diabetes Research Plan  
2000-2001 Member, Israeli Women Health Committee  
2000- Consulting Endocrinologist, Chief Physician's Office, Israeli Defense Forces  
2002- Member of National Institute of Health - steering committee  
2003- Head of National Board / Task Force of Diabetes of Ministry of Health  
2004- Present Head, Israel National Diabetes Council

**Membership in Scientific and Medical Societies:**

- American Association for the Advancement of Science
- Israeli Society for Internal Medicine (Secretary 1990 - 1993)
- Israel Diabetes Association (President since 1993)
- American Diabetes Association
- European Association for the Study of Diabetes
- International Diabetic Federation
- Cell Transplant Society
- Israeli Transplant Society
- Israeli Medical Association

**List of Publications:**

- 1) Siegal T, Raz I, Polliack A. Nervous system involvement in malignant lymphoma. *Harefuah* 103(10):251-254,1982.
- 2) Raz I, Haas H. Tuberculous axillary lymphadenitis - an unusual presentation. *Tubercle* 64:41-42,1983.
- 3) Shaked A, Raz I, Gottehrer A, Romanoff H. Asymptomatic, highly vascularized superior mediastinal mass. *Chest* 86(4):621-622,1984.
- 4) Raz I, Gottlieb D, Bar-On H. Acute dysphasia associated with hypoglycemia. *Is J Med Sc* 20(8):729-730,1984.
- 5) Raz I, Katz M, Aram H, Haas H. Sporitrichoid *Myobacterium marinum* infection: Report of a ten year case. *Int J Dermatol* 23(8):554-555,1984.

- 6) **Raz I, Or R, Okon E, Leizerwitz R, Polliack A.** Hairy cell leukemia: report of an unusual case with hepatomegaly due to a large vascular tumor of the liver, mediastinal mass and pleural effusion containing hairy cells. *Acta Haematol* 71(6):393-399,1984.
- 7) **Leitersdorf E, Israeli A, Raz I.** Anorexia nervosa - an unusual presentation of the Plummer-Vinson syndrome. *Int J Psych Med* 14:343-346,1984.
- 8) **Weiss AT, Flugelman MY, Lewis BS, Raz I, Halon DA, Gotsman M.** Isolated right ventricular infarction with ventricular tachyarrhythmia. *Am Heart J* 108(2): 425-426, 1984.
- 9) **Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O.** Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. *Isr J Med Sci* 20 (1): 46-49, 1984.
- 10) **Raz I, Polliack A.** Coexistence of myelomonocytic leukemia and monoclonal gammopathy or myeloma. Simultaneous presentation in three patients. *Cancer* 53 (1): 83-85, 1984.
- 11) **Raz I, Shinar E, Polliack A.** Pancytopenia with hypercellular bone marrow. A possible paraneoplastic syndrome in carcinoma of the lung. A report of three cases. *Am J Hematol* 16 (4): 403-408,1984.
- 12) **Raz I, Bar-On H, Kidron M, Ziv E.** Rectal administration of insulin. *Isr J Med Sci* 20 (2):173-175,1984.
- 13) **Raz I, Bialer M, Salame K, Bar-On H.** Comparative pharmacokinetic analysis of a novel sustained - release dosage form of theophylline in humans. *Eur J Clin Pharmacol* 26 (3): 401-403, 1984.
- 14) **Hass H, Katz M, Raz I** Isolation of the new species, *Mycobacterium fallax* in Israel. *Isr J Med Sci* 20 (11):1097-1098,1984.
- 15) **Raz I, Siegal T, Polliack A.** CNS involvement by non-Hodgkin's lymphoma: Response to a standard therapeutic protocol. *Arch Neurol* 41 (11): 1167-1171,1984.
- 16) **Raz I, Koffler M, Leitersdorf E, Bar-On H.** Maintenance of ambulatory diabetic patients on subcutaneous insulin pump. *Isr J Med Sci* 20 (8): 731-735, 1984.
- 17) **Bialer M, Rubinstein A, Raz I, Abramsky O.** Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. *Eur J Clin Pharmacol* 27 (4):501-503, 1984.
- 18) **Bialer M, Salame K, Raz I** Effect of sustained release on the pharmacokinetics of theophylline in healthy subjects. *Int J Clin Pharmacol Ther Toxicol* 23 (12): 662-667,1985.
- 19) **Or R, Raz I, Polliack A.** Hairy cell leukemia associated with carcinoma. *Blut* 50 (5): 299-301, 1985.
- 20) **Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F.** Pharmacokinetics of valproic acid in volunteers after a single dose study. *Biopharm Drug Dispos* 6(1): 33-42,1985.
- 21) **Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O.** Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. *Biopharm Drug Dispos* 6 (4): 401-411,1985.
- 22) **Raz I, Fisher S, Israeli A, Gottehrer N, Chisin R, Kleinman Y.** An unusual case of rheumatic pneumonia. *Arch Int Med* 145(6):1130-1131,1985.

- 23) Rubinstein A, Bialer M, Frieman M, Raz I, Abramsky O. A combined approach to control valproic acid - a kinetic and pharmacokinetic study. *J Control Release* 4:33-38,1986.
- 24) Hussein Z, Bialer M, Friedman M, Raz I. Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. *Biopharm. Drug Dispos* 8 (5): 427-435, 1987.
- 25) Micaeli J, Lugassy G, Raz I, Uzieli B, Polliack A. Chronic lymphocytic leukemia and malignant lymphoma developing in patients with autoimmunity or other ill-defined immune stigmata: a review of the literature and report of an additional 9 cases. *Hematol Rev* 1: 291-310, 1987.
- 26) Raz I, Leitersdorf E, Kleinman Y. Acute bilateral brachial plexus neuritis associated with hypersensitivity vasculitis. A case report and review of the literature. *Klin Wochenschr* 63(14): 643-645,1985.
- 27) Or R, Raz I, Rave D, Lichovitzki G, Kleinman Y. Thymoma presenting as a superior vena cava syndrome remission following therapy. *Klin Wochenschr* 65(13): 617-619,1987.
- 28) Caraco Y, Rave D, Raz I. Shigella sonnei myocarditis. *Clin Cardiol* 10(7): 423-424, 1987.
- 29) Raz I. Hyperglycemia – its relation to diabetic neuropathy. *Harefuah* 112: 22-25, 1987 (Hebrew).
- 30) Raz I. Diabetic nephropathy. Treatment with low protein diet. *Harefuah* 113 (3, 4): 75-77,1987 (Hebrew).
- 31) Haas H, Raz I, Katz S. Tuberculous cervical lymphadenitis. *Harefuah* 112: 297-299,1987 (Hebrew).
- 32) Arnon R, Raz I, Chajek-Shaul T, Berkman N, Field S, Bar-On H. Amiodarone pulmonary toxicity presenting as a solitary lung mass. *Chest* 93(2):425-427, 1988.
- 33) Raz I, Soskolne V, Stein P. Influence of small group education sessions on glucose hemostasis in NIDDM. *Diabetes Care* 11 (1): 67- 71, 1988.
- 34) Raz I, Havivi E. Influence of chronic diabetes on tissue and blood cells status of zinc, copper and chromium in the rat. *Diabetes Res* 7 (1): 19-23, 1988.
- 35) Raz I, Ben David J, Hussein Z, Samara E. Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects. *Int J Clin Pharmacol Ther Toxicol* 26 (4): 206-208, 1988.
- 36) Raz I, Hussein Z, Samara E, Ben-David J. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of diclofenac sodium in healthy subjects. *Int J Clin. Pharmacol. Ther. Toxicol* 26 (5): 246-248, 1988.
- 37) Raz I, Rosenblit H, Kark JD. Effect of moderate exercise on serum lipids in young men with low high density lipoprotein cholesterol. *Arteriosclerosis* 8 (3): 245-251, 1988.
- 38) Raz I, Hasdai D, Seltzer Z, Melmed RN. Effect of hyperglycemia on pain perception and on efficacy of morphine analgesia in rats. *Diabetes* 37 (9): 1253-1259, 1988.
- 39) Raz I, Adler JH, Havivi E. Altered tissue content of trace metals in diabetic hyperinsulinaemic sand rats (*Psammomys obesus*). *Diabetologia* 31 (5): 329-333, 1988.

- 40) Raz I, Havivi Y, Yarom R. Reduced negative surface charges on arterial endothelium of diabetic rats. *Diabetologia* 31 (8): 618-620, 1988.
- 41) Raz I, Israeli A, Rosenblit H, Bar-On H. Influence of moderate exercise on glucose homeostasis and serum testosterone in young men with low HDL-cholesterol level. *Diabetes Res* 9 (1): 31-35,1988.
- 42) Caraco Y, Arnon R, Raz I. Atrioventricular block complicating acute streptococcal tonsillitis. *Br Heart J* 59(3): 389-390,1988.
- 43) Caraco Y, Raveh D, Flugelman M, Raz I. Enhanced anticoagulation effect of acenocoumarol induced by amyodarone coadministration. *Isr J Med Sci* 24: 688-689, 1988.
- 44) Israeli A, Matzner Y, Or R, Raz I. Gibenclamida causing thrombocytopenia and bleeding tendency: case reports and review of the literature. *Klin Wochenschr* 66(5): 223-224,1988.
- 45) Raz I, Okon E, Chajek-Shaul T. Pulmonary manifestations in Behcet's syndrome. *Chest* 95 (3): 585 - 589,1989 (Review).
- 46) Raz I, Havivi E. Trace elements in blood cells of diabetic subjects. *Diabetic Res* 10 (1): 21-24, 1989.
- 47) Raz I, Karsai D, Katz M. The influence of zinc supplementation on glucose homeostasis in NIDDM. *Diabetes Res* 11 (2): 73-79,1989.
- 48) Zusman I, Yaffe P, Raz I, Bar-On H, Ornoy A. Effects of human diabetic serum on the in vitro development of early somite rat embryos. *Teratology* 39 (1): 85-92,1989.
- 49) Kidron M, Krausz M, Raz I, Baron H, Ziv E. The absorption of insulin from dog intestine is facilitated by bile acids. *Tenside Surf Det* 26: 352-354, 1989.
- 50) Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner J. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. *New Engl J Med* 323 (6): 373-378,1990.
- 51) Zurlo F, Lillioja S, Esposito-Del-Puente A, Nyomba BL, Raz I, Saad MF, Swinburn BA, Knowler WC, Bogardus C, Ravussin E. Low ratio of fat to carbohydrate oxidation as predictor of weight gain – study of 24-h RQ. *Am J Physiol* 259 (5 Pt 1): E650-657,1990.
- 52) Harats D, Manny H, Raz I. Autoimmune hemolytic anemic in Gaucher's disease. *Klin Wochenschr* 68(2):94-95,1990.
- 53) Caraco Y, Arnon R, Raz I. Bethanechol induced cholinergic toxicity in diabetic neuropathy. *DICP* 24(3):327-328,1990.
- 54) Harats D, Raz I, Lebensart P. Ultrasonographic appearance of well defined splenic space-occupying lesions in Gaucher's disease. *Isr J Med Sci* 26(3):168-170,1990.
- 55) Nyomba BL, Freymond D, Raz I, Stone K, Mott DM, Bogardus C. Skeletal muscle glycogen synthase activity in subjects with non-insulin dependent diabetes mellitus after glyburide therapy. *Metabolism* 39 (11):1204-1210,1990.
- 56) Raz I, Katz A, Spencer K. Ephinephrine inhibits insulin-mediated glycogenesis but enhances glycolysis in human skeletal muscle. *Am J Physiol* 260 (3 pt 1):E430-435,1991.
- 57) Spencer MK, Katz I, Raz I. Ephinephrine increases tricarboxylic acid cycle intermediates in human skeletal muscle. *Am J Physiol* 260 (3 pt 1): E436-439,1991.
- 58) Katz A, Raz I, Spencer M K, Rising R, Mott MD. Hyperglycemia induces accumulation of glucose in human skeletal muscle. *Am J Physiol* 260 (4 pt 2): R698-703,1991.

- 59) Maeda R, Raz I, Zurlo F, Sommercorn J. Activation of skeletal muscle casein kinase II by insulin is not diminished in subjects with insulin resistance. *J Clin Invest* 87(3): 1017-1022, 1991.
- 60) McGuire MC, Fields RN, Nyomba B L, Raz I, Bogardous C, Tonks NK, Sommercorn J. Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. *Diabetes* 40(7):939-942,1991.
- 61) Swinburn BA, Nyomba BL, Saad MF, Zurlo F, Raz I, Knowler WC, Lillioja S, Bogardus C, Ravussin E. Insulin resistance associated with lower rates of weight gain in Pima Indians. *J. Clin Invest* 88(1):168-173,1991.
- 62) Havivi E, Bar On H, Reshef A, Stein P, Raz I. Vitamins and trace metals status in non insulin dependent diabetes mellitus. *Int J Vit Nutr Res* 61(4):328-333,1991.
- 63) Kida Y, Raz I, Maeda R, Nyomba B L, Stone K, Bogardus C, Sommercorn J, Mott DM. Defective insulin response of phosphorylase phosphatase in insulin-resistant humans. *J Clin Invest* 89 (2):610-617,1992.
- 64) Raz I, Levinger S, Maravi Y, Sigelmann N, Shananas M, Bursztyn M. Prevalence of glucose intolerance in young male Ethiopian immigrants. *Isr J Med Sci* 29 (6-7): 347-350,1993.
- 65) Bursztyn M, Raz I. Blood pressure, glucose, insulin and lipids of young Ethiopian recent immigrants to Israel and in those resident for 2 years. *J Hyperten* 11 (4): 455-459,1993.
- 66) Raz I, Chigier E, Rosenblit H, Mevorach R, Bursztyn M. Comparison of glucose tolerance, lipids and blood pressure in young male Ethiopians from two different immigrations – 1989 and 1991. *Isr J Med Sci* 29 (6-7): 351-354,1993.
- 67) Bursztyn M, Ben-Ishay D, Shochina M, Mekler J, Raz I. Disparate effects of exercise training on glucose tolerance and insulin levels and on ambulatory blood pressure in hypertensive patients. *J Hypertens* 11(10):1121-1125,1993.
- 68) Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Chronic exogenous hyperinsulinemia without sugar supplementation: acute salt-sensitive hypertension without changes in resting blood pressure. *J Hypertens* 11(7): 703-707,1993.
- 69) Sommercorn J, Fields R, Raz I, Maeda R. Abnormal regulation of ribosomal protein S6 kinase by insulin in skeletal muscle of insulin-resistant humans. *J Clin Invest* 91 (2):509-513, 1993.
- 70) Bursztyn M, Raz I, Mekler J, Ben-Ishay D. Nitrendipine improves glucose tolerance and deoxyglucose uptake in hypertensive rats. *Hypertension* 23 (6 pt 2): 1051-1053,1994.
- 71) Raz I, Hauser E, Bursztyn M. Moderate exercise improves glucose metabolism in uncontrolled elderly patients with non-insulin-dependent diabetes mellitus. *Isr J Med Sci* 30 (10):766-770,1994.
- 72) Bialer M, Phara JZ, Zuckerman S, Raz I, Abramsky O, Sterling J, Ladkani D. Pharmacokinetic analysis of valdice diethylcarbonate product of acid. *Eur J Pharm Sci* 2: 239-244,1994.
- 73) Katz A, Raz I. Hexokinase kinetics in human skeletal muscle after hyperinsulinaemia, hyperglycemia and hyperepinephrinaemia. *Acta Physio Scand* 151 (4):527-530,1994.
- 74) Raz I, Gilhar D, Hoffman A. Prolonged response to Glibenclamide in NIDDM patients in a normoglycemic state. *Isr J Med Sci* 30 (10):775-778,1994.

- 75) Hoffman A, Fischer Y, Gilhar D, Raz I. The effect of hyperglycemia on the absorption of glibenclamide in patients with non-insulin dependent diabetes mellitus. *Eur J Clin Pharmacol* 47 (1):53-55,1994.
- 76) Raz I. Exocrine insufficiency in transplanted pancreas imitating pancreatic rejection. *Diabetes Care* 17(7): 779-780,1994.
- 77) Bursztyn M, Raz I, Ben-Ishay D. Blood pressure measurement method not responsible for results of Brands et al (Letter). *Am J Hypertens* 7(11):1033, 1994.
- 78) Katz A, Raz I. Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation. *Pflugers Arch* 431(2):259-265,1995
- 79) Bursztyn M, Raz I. Prediction of hypertension by the insulinogenic index in young Ethiopian immigrants. *J Hypertens* 13(1):57-61,1995.
- 80) Philip M, Landau D, Segev Y, Weiss O, Raz I. Insulin-like growth factors (IGFs) and IGF-binding protein in diabetic kidney disease. *Isr J Med Sci* 31(12):712-716,1995.
- 81) Weiss O, Anner H, Nephesh I, Alayoff A, Bursztyn M, Raz I. Insulin-like growth factor-I (IGF-I) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. *Metabolism* 44(8):982-986,1995.
- 82) Friedlander M, Popovtzer MM, Weiss O, Nefesh I, Kopolovic J, Raz I. Insulin-like growth factor -1 (IGF-1)enhances recovery from HgC12-induced acute renal failure: the effects on renal IGF- 1, IGF -1 receptor and IGF-binding protein-1 mRNA. *J Am Soc Nephrol* 5 (10): 1782-1791,1995.
- 83) Bursztyn M, Raz I. Blood pressure and insulin in Ethiopian immigrants: Longitudinal study. *J Hum Hypertens* 9 (4): 245-248, 1995.
- 84) Meirow D, Yossepowitch O, Rosler A, Brezezinski A, Schenker JG, Laufer N, Raz I. Insulin resistant and non-resistant polycystic ovary syndromes represent two distinct clinical and endocrinological subgroups. *Hum Reprod* 10 (8):1951-1956, 1995.
- 85) Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Chronic exogenous hyperinsulinemia accelerates the development of hypertension in spontaneously hypertensive rats. *Clin Exp Pharmacol Physiol Suppl* 22 (1): S28-29,1995.
- 86) Bursztyn M, Ben-Ishay D, Mekler J, Raz I. Insulin induced renal dysfunction in regular Sabra rats. *Clin Exp Pharmacol Physiol Suppl* 22 (1): S32-33, 1995.
- 87) Ornoy A, Zaken V, Abir R, Yaffe P, Raz I. Effects on rat embryos of culture in serum of women with gestational diabetes. *Toxic in Vitro* 9: 643-651, 1996.
- 88) Ornoy A, Kimyagarov D, Yaffee P, Abir R, Raz I, Kohen R. Role of reactive oxygen species in diabetes induced embryotoxicity: studies on pre-implantation mouse embryos cultured in serum from diabetic pregnant women. *Isr J Med Sci* 32(11): 1066-1073, 1996.
- 89) Leibowitz G, Tsur A, Chayen SD, Salameh M, Raz I, Cerasi E, Gross DJ. Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients. *Clin Endocrino Oxf* 44 (6): 717 - 722, 1996.
- 90) Meirow D, Raz I, Yossepowitch O, Brzezinski A, Rosler A, Schenker JG, Berry EM. Dyslipidemia in polycystic ovarian syndrome: different groups, different etiologies? *Hum Reprod* 11(9):1848-1853, 1996.
- 91) Cohen SE, Raz I, Safadi R. A patient with hypoparathyroidism, dysmorphic features and mental retardation. *Eur J Med Res* 1(5): 266-268,1996. (Review)

- 92) Schulz-Knappe SE, Raz I, Safadi R. A patient with hypoparathyroidism, dysmorphic features and mental retardation. *Eur. J Med Res* 1: 266-268, 1996.
- 93) Bursztyn M, Raz I, Mekler J, Ben-Ishay D. Effect of acute N-nitro-L-arginine methyl ester (L- NAME) hypertension on glucose tolerance, insulin levels and [3H] deoxyglucose muscle uptake. *Am J Hypertens* 10(6):683-686, 1997.
- 94) Raz I, Rubinger D, Popovtzer M, Gronback H, Weiss O, Flyvbjerg A. Octreotide prevents the early increase in renal insulin-like growth factor binding protein 1 in streptozotocin in diabetic rats. *Diabetes* 47(6):924-930, 1998. Erratum in *Diabetes* 47(7): 1170, 1998.
- 95) Rubinger D, Weiss O, Zarfati D, Popovtzer MM, Raz I. The effect of low dose octreotide administration on renal function and on gene expression of IGF-I axis components in experimental diabetes mellitus. *J Endocrinol* 159(1): 133-140, 1998.
- 96) Mosseri M, Nahir M, Rozenman Y, Lotan C, Admon D, Raz I, Gotsman MS. Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. *Cardiology* 89 (2): 103-110, 1998.
- 97) Averbukh E, Weiss O, Halpert M, Yanko R, Moshe R, Nephesh I, Flyvbjerg A, Yanko L, Raz I. Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. *Metabolism* 47 (11): 1331-1336, 1998.
- 98) Symon Z, Fuchs S, Agmon Y, Weiss O, Nephesh I, Moshe R, Brezis M, Flyvbjerg, A, Raz I. The endogenous insulin-like growth factor system in radiocontrast nephropathy. *Am J Physiol* 274 (3 Pt 2): F490-497, 1998.
- 99) Cohen Y, Raz I, Merin G, Mozes B. Comparison of factors associated with 30 day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. *Am. J. Cardiol* 81 (1): 7-11, 1998.
- 100) Hirshberg B, Trelezky V, Raz I. Hypoglycaemia following pancreatic allograft transplantation. *J Int Med* 243 (5):389-393, 1998.
- 101) Lomnický Y, Friedman M, Luria MY, Raz I, Hoffman A. The effect of the mode of administration on the hypolipidaemic activity of Niacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats. *J Pharm. Pharmacol* 50 (11): 1233-1239, 1998.
- 102) Mumcuoglu KY, Ingber A, Gilead L, Stessman J, Friedmann R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Maggot therapy for the treatment of diabetic foot ulcers (Letter) *Diabetes Care* 21:2030-2031, 1998.
- 103) Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. *Gut* 44 (5):704-8, 1999.
- 104) Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. *J Autoimmun* 12 (2):121-129, 1999.
- 105) Mumcuoglu KY, Ingber A, Gilad L, Stessman J, Friedman R, Schulman H, Bichucher H, Ioffe-Uspensky I, Miller J, Galun R, Raz I. Maggot therapy for the treatment of intractable wounds. *Int J Dermatol* 38(8):623-627, 1999.
- 106) Datta U, Wexler ID, Kerr DS, Raz I, Patel MS. Characterization of the regulatory region of the human testis-specific form of the pyruvate dehydrogenase alpha-subunit (PDHA-2) gene. *Biochim Biophys Acta* 1447 (2-3):236-43, 1999.

- 107) Sade K, Schwartz D, Wolman Y, Schwartz I, Chernichovski T, Blum M, Brazowski E, Keynan S, Raz I, Blantz RC, Iaina A. Time course of lipopolysaccharide-induced nitric oxide synthase mRNA expression in rat glomeruli. *J Lab Clin Med* 134(5): 471-7, 1999.
- 108) Stern E, Raz I, Weitzman S. Prevalence of diabetes mellitus among workers in Israel: a nation-wide study. *Acta Diabetol* 36(4): 169-72, 1999.
- 109) Keynan S, Hirshberg B, Levine-Iaina N, Wexler ID, Dahan R, Reinhartz E, Ovadia, H., Wollman Y, Chernihovskiy T, Iaina A, Raz I. Renal nitric oxide production during the early phase of experimental diabetes mellitus. *Kidney Int* 58 (2): 740-7, 2000.
- 110) Shpichinetsky V, Raz I, Friedlander Y, Goldschmidt N, Wexler ID, Ben-Yehuda A, Friedman G. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. *J Nutr* 130 (10): 2493-7, 2000.
- 111) Raz I, Wexler ID. Biomedical research in Israel: does it have a future? *Isr Medical Assoc J* 2 (7): 495-8, 2000.
- 112) Averbukh E, Halpert M, Yanko R, Yanko L, Peer J, Levinger S, Flyvbjerg A, Raz I. Octreotide a somatostatin analogue fails to inhibit hypoxia-induced retinal neovascularisation in the neonatal rat. *Int J Exp Diabetes Res* 1 (1):39-47, 2000.
- 113) Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic – pharmacodynamic rationale for oral CR metformin formulation. *J Control Release* 71 (1):107-15, 2001.
- 114) Bursztyjn M, Flyvbjerg A, Weiss O, Mekler J, Raz I. Atrophy or hypertrophy in chronic renal ischemia: roll of the IGF-I system. *Am J Hypertens* 14 (12): 1211-1218, 2001.
- 115) Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta–cell function in new-onset type 1 diabetes by specific immunomodulation with heat shock protein peptide (Diapep 277): a randomized, double-b phase II trial. *Lancet* 358 (9295):1749-53, 2001.
- 116) Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Polh M, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Eng J Med* 345(12):851-860, 2001.
- 117) Wainstein J, Metzger M, Wexler ID, Cohen J, Raz I. The use of continuous insulin delivery systems in severely insulin-resistant patients. *Diabetes Care* 24 (7):1299, 2001.
- 118) Raz I. Editor's Foreword. *Diabetes Obes Metab* 3 suppl 1:1-2, 2001.
- 119) Wainstein J, Metzger M, Minuchin O, Harmann I, Cohen Y, Jaffe A, Raz I. Pump treatment for severely insulin resistant diabetic patients (Letter). *Diabetes Care* 24: 7 1299, 2001.
- 120) Metzger M, Leibowitz G, Wainstein J, Glaser B, Raz I. Reproducibility of glucose measurements using the glucose sensor. *Diabetes Care* 25 (7): 1185-91, 2002.
- 121) Khamaisi M, Flyvbjerg A, Haramati Z, Raz G, Wexler ID, Raz I. Effect of mild hypoinsulinemia on renal hypertrophy: growth hormone/insulin –like growth factor I system in mild streptozotocin diabetes. *Int J Exp Diabetes Res* 3 (4):257-64, 2002.
- 122) Tepensky D, Friedman M, Raz I, Hoffman A. Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. *Drug Metab Dispos* 30(8):861-8, 2002.

- 123) Khamaisi M, *Raz I*. Diabetes epidemic and the thrifty gene. *Isr Med Assoc J* 4 (9): 720-721, 2002.
- 124) *Raz I*, Wexler I, Weiss O, Flyvbjerg A, Segev Y, Rauchwerger A, Raz G, Khamaisi M. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat). *Nephrol Dial Transplant* 18 (7):1293-8, 2003.
- 125) Khamaisi M, Schrijvers BF, De Vriese AS, *Raz I*, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. *Nephrol Dial Transplant* 18 (8):1427-30, 2003.
- 126) *Raz I*, Rosengarten Y, Carasso R. Correlation study between conventional medical diagnosis and the diagnosis by reflexology (non-conventional). *Harefuah* 143(8-9): 600-605, 646, 2003. (Hebrew)
- 127) Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PI, Esmatjes E, Hricik D, Parikh CR, *Raz I*, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial (IDNT) of Patients with Type 2 diabetes and overt nephropathy. *Ann Inter Med* 138 (7):542-549, 2003 [Summary for patients in *Ann Inter Med*. 138(7):143, 2003]
- 128) Roth A, Kalter-Leibovici O, Kerbis Y, Tenenbaum-Koren E, Chen J, Sobol T, *Raz I*. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. *Clin Cardiol* 26 (1):25-30, 2003.
- 129) Khamaisi M, Wainstein J, Hancu N, Milicevic Z, *Raz I*. Association of hyperglycemia and insulin with diabetic cardiovascular complications. *Isr Med Assoc J* 5 (2):116-9, 2003.
- 130) Shafrir E, *Raz I*. Diabetes: mellitus or lipidus? *Diabetologia* 46 (3):433-40, 2003.
- 131) Shafrir E, *Raz I*. Diabetes: mellitus or lipidus? Author's reply. *Diabetologia* 46 (11): 1587, 2003.
- 132) Gronbaek H, Tanos V, Meirow D, Peretz T, *Raz I*, Flyvbjerg A. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. *Anticancer Res* May- Jun 23 (3C):2815-20, 2003.
- 133) Bursztyn M, Podjarny E, Dahan R, *Raz I*, Bernheim J. Insulin-induced hypertension, L-arginine, and endothelial nitric oxide synthase in pregnant rats. *Hypertens Pregnancy* 22 (3):267-74, 2003.
- 134) Khamaisi M, Wexler ID, Shrha J, Strojek K, *Raz I*, Milicevic Z. Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities. *Isr Med Assoc J* 5 (11):801-6, 2003.
- 135) Milicevic Z, *Raz I*. Interventions in diabetic patients after myocardial infarction. *Acta Diabetol.* 40 *Suppl* 2:S348-53, 2003.
- 136) Cernea S, Hancu N, *Raz I*. Diet and coronary heart disease in diabetes. *Acta Diabetol*, 40 *suppl* 2:S389-400, 2003.
- 137) *Raz I*, Mouritzen U, Vaz J, Hershkovitz T, Wainstein J, Boehm I. Addition of biphasic insulin aspart 30 to rosiglitaxone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. *Clin Ther* 25 (12):3109-23, 2003.
- 138) Elazary AS, Lador N, Shauer A, Meir K, Pollak A, Wolf DG, *Raz I*, Leitersdorf E, Mevorach, D. Tongue necrosis and pericarditis. *Lancet* 363 (9413):948, 2004.

- 139) Keynan S, Khamaisi M, Dahan R, Barnes K, Jackson CD, Turner AJ, *Raz I*. Increased expression of endothelin-converting enzyme- 1c isoform in response to high glucose levels in endothelial cells. *J Vasc Res* 41(2):131-40, 2004.
- 140) Abdul-Ghani MA, Sabah M, Minuchin O, Vardi P, *Raz I*, Wainstein J. Primary prevention of type 2 diabetes: how do we do it? *Isr Med Asso J*. 6 (5):305-7, 2004.
- 141) Tsur A, Harman-Boehm I, Wainstein J, *Raz I*. Primary care for type 2 diabetes: *Harefuah* 143(5); 353-354, 2004. (Hebrew)
- 142) Anis Y, Leshem O, Reuveni H, Wexler I, Ben Sasson R, Yahalom B, Laster M, *Raz I*, Ben- Sasson S, Shafir E, Ziv E. Antidiabetic effect of novel modulating peptides of G-protein-coupled kinase in experimental models of diabetes. *Diabetologia* 47(7): 1232-1244, 2004.
- 143) Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, *Raz I*, Vanhille P, Locatelli F, Goldhaber S, Lewish EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. *Kidney Int Suppl* 92:S50-55, 2004. Review
- 144) Eldor R, *Raz I*, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. *Diabet Med* 21(11):1161-1173, 2004. Review.
- 145) Raslova K, Boboev M, *Raz I*, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. *Diabetes Res Clin Pract* 66(2):193-201, 2004.
- 146) Cernea S, Kidron M, Wohlgelernter J, Modi P, *Raz I*. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. *Clin Ther* 26(12): 2084-2091, 2004.
- 147) *Raz I*, Eldor R, Cernea S, Shafir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. *Diabetes Metab Res Rev* 21(1):3-14, 2005. Review.
- 148) Fujioka K, Brazg RL, *Raz I*, Bruce S, Joyal S, Swanink R, Pans M. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. *Diabetes Obes Metab* 7(1):28-39, 2005
- 149) *Raz I*, Eldor R, Naparstek Y. Immune modulation for prevention of type 1 diabetes mellitus. *Trends Biotechnol* 23(3):128-134, 2005. Review.
- 150) Milicevic Z, *Raz I*, Strojek K, Skrha J, Tan MH, Wyatt JW, Beattie SD, Robbins DC; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction of cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. *J Diabetes Complications* 19(2):80-87, 2005.
- 151) Abdul-Ghani MA, Sabbah M, Muati B, Dakwar N, Kashkosh H, Minuchin O, Vardi P, *Raz I*. High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. *Isr Med Assoc J* 7(3):143-147, 2005.
- 152) Eldor R, *Raz I*. Lipids and glucose in type 2 diabetes: What about the beta-cell and the mitochondria? Response to Boden and Laakso. *Diabetes Care* 28(4):985-986, 2005. (Author reply, 986-987).

- 153) Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. *Diabetes* 54(5):P1487-1496, 2005.
- 154) Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Dose-response relationship of oral insulin spray in healthy subjects. *Diabetes Care* 28(6):1353-1357, 2005.
- 155) Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. *J Am Soc Nephrol* 16(7): 2170-2179, 2005.
- 156) Hillel J, Gefel D, Kalman R, Ben-Ari G, David L, Orion O, Feldman MW, Bar-On H, Blum S, Raz I, Schaap T, Shpirer I, Lavi U, Shafir E, Ziv E. Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in *Psammomys obesus*. *Heredity* 95(2):158-165, 2005.
- 157) Eldor R, Stern E, Milicevic A, Raz I. Early use of insulin in type 2 diabetes. *Diabetes Res Clin Pract* Suppl 1:S30-35, 2005.
- 158) Kalter-Leibovici O, Wainstein J, Ziv A, Harman-Boehm I, Murad H, Raz I; Israel Diabetes Research Group (IDRG) Investigators. Clinical, socioeconomic and lifestyle parameters associated with erectile dysfunction among diabetic men. *Diabetes Care* 28(7):1739-1744, 2005.
- 159) Raz I. Complex impact of obesity on type 2 diabetes. *Isr Med Assoc J* 7(6):402-403, 2005.
- 160) Raz I. Peace building through health in Israel and Palestine. *Lancet* 366(9479):26. Letter, 2005.
- 161) Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. *Diabet Med* 22(8):1037-1046, 2005.
- 162) Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, Chow CC, Shaban J. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. *Clin Ther* 27(9): 1432-43, 2005.
- 163) Eldor R, Cohen IR, Raz I. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus. *Int Rev Immunol* 24(5-6): 327-39, 2005.
- 164) Cernea S, Kidron M, Wohlgelernter J, Raz I. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. *Clin Ther* 27(10):1562-70, 2005.
- 165) Khamaisi M, Keynan S, Bursztyn M, Dahan R, Reinhartz E, Ovadia H, Raz I. Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. *Nephron Physiol* 102(3-4):72-80, 2006.
- 166) Abdul-Ghani MA, Sabbah M, Kher J, Minuchin O, Vardi P, Raz I. Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. *Diabetes Metab Res Rev* 22(2):126-30, 2006.
- 167) Knobler H, Benderly M, Boyko V, Behar S, Matas Z, Rubinstein A, Raz I, Wainstein J. Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. *Eur J Endocrinol* 154(1):87-92, 2006.

- 168) Cernea S, *Raz I*. Noninjectable methods of insulin administration. *Drugs of Today* 42(6):405-424, 2006
- 169) Szalat A, *Raz I*. Metabolic syndrome and microangiopathy. *Isr Med Assoc J* 8(6): 424-425, 2006
- 170) Weiss R, *Raz I*. Focus on childhood fitness, not just fatness. *Lancet* 368(9532): 261-262, 2006.
- 171) *Raz I*. Introduction. *Diabetes Res Clin Pract* 74 Suppl 1:S1-2, Epub 2006
- 172) Eldor R, *Raz I*. Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. *Diabetes Res Clin Pract* 74 Suppl 1:S3-8. Epub 2006
- 173) Tsur A, Harman-Boehm I, Buchs AE, *Raz I*, Wainstein J. The guidelines for the diagnosis, prevention and treatment of type 2 diabetes mellitus – 2005. *Harefuah* 145(8):583-6, 630, 2006 (Hebrew)
- 174) Ziegler D, Ametov A, Barinov A Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, *Raz I*, Novosadova M, Maus J. Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. *Diabetes Care* 29(11):2365-70, 2006
- 175) Elias D, Avron A, Tamir M, *Raz I*. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. *Ann NY Acad Sci* 1079:340-4, 2006
- 176) Cernea S, *Raz I*. Noninjectable methods of insulin administration. *Timely Top Med Cardiovasc Dis*10;E29, 2006 Review
- 177)Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, *Raz I*, Elad S. Possible association between diabetes and bisphosphonate-related jaw osteoneonecrosis. *J Clin Endocrinol Metab* 92(3):1172-5, 2007
- 178) Yagil C, Barkalifa R, Sapojnikov M, Wechsler A, Ben-Dor D, Weksler-Zangen S, Kaiser N, *Raz I*, Yagil Y. Metabolic and genomic dissection of diabetes in the Cohen rat. *Physiol Genomics* Jan 9, 2007
- 179) Ryden L, Stankl E, Barnik M, Vanden Berghe G, Betteridge J, de Boer MJ, Cosentino F, Honsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregro K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Chabonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro Pf, Parhofer K, Pyorala K, *Raz I*, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) *Eur Heart J* 28(1):88-136, 2007
- 180) Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, *Raz I*. Predicting the 20-year diabetes incidence rate. *Diabetes Metab Res Rev* Oct;23(7):551-558, 2007
- 181)Weiss R, Yegorchikov Y, Shusterman A, *Raz I*. Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects. *Diabetes Technol Ther* 9(1):68-74, 2007
- 182) *Raz I*. Sitagliptin: a viewpoptint by *Itamar Raz*. *Drugs* 67(4):598-9, 2007

- 183) Paamoni-Keren, O, Silberstein T, Burg A, Raz I, Mazor M, Saphier O. Oxidative stress as determined by glutathione (GSH) concentrations in venous cord blood in elective cesarean delivery versus uncomplicated vaginal delivery. *Arch Gynecol Obstet Jul*;276(1):43-46, 2007
- 184) Khamaisi M, Sondergaard M, Segev Y, Dagnaes-Hansen F, Jensen TG, Landau D, Raz I, Flyvbjerg A. Differential effects on kidney and liver growth of a non-viral hGh-expression vector in hypophysectomized mice. *Growth Horm IGF Res Aug*;17(4): 279-287, 2007
- 185) Ilinav H, Wolf Z, Szalat A, Bdolah-Abram T, Glaser B, Raz I, Leibowitz G. In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment. *Curr Med Res Opin Apr*;23(4):757-765. 2007-12-05
- 186) Raz I, Eldor R. New treatments for diabetes. *N Engl J Med May 24*; 356(21):2222, author reply 2222-3.
- 187) Bakris GI, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. *Kidney Int Oct*;72(7): 879-885, 2007
- 188) Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology July 17*, 2007 (Epub ahead of print)
- 189) Shai I, Wainstein J, Harman-Boehm I, Raz I, Fraser D, Rudich A, Stampfer MJ. Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. *Diabetes Care Dec*;30(12): 3011-3016, 2007
- 190) Naor D, Nedvetzki S, Walmasley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assaya-Asherie N, Raz I, Weiss L, Slavin S, Golan I. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. *Ann NY Acad Sci Sep*; 1110:233-247, 2007
- 191) Weksler-Zangen S, Raz I, Lenzen S, Jorns A, Ehrenfeld S, Amir G, Oprescu A, Yagil Y, Yagil C, Zangen DH, Kaiser N. Impaired glucose stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. *Diabetes Oct 31*, 2007 [Epub ahead of print], PMID:17977959
- 192) Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. *Drugs 67(18)*:2681-2696, 2007
- 193) Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB; for the Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. *Nephrol Dial Transplant 2007 Dec 18*; [epub ahead of print] PMID: 18089623

#### Editor-Books

1. Diabetes in the Third Millenium, Published by the Israel Diabetes Association, Tel-Aviv, 2002
2. M Dunitz - Diabetes: From Research to Diagnosis and Treatment. Edited by Raz I, Skyler J and Shafir E. Published by M. Dunitz, Taylor and Francis Associates U.K. 2002.

#### Chapters in Books:

1. Michaeli JU, Lugassy G, Raz I, Polliack A. Chronic lymphocytic leukemia. Chapter 17. A. Polliack, and D. Catovsky, editors, Harwood Academic Publishers. London - New York, pp. 231-248, 1988
2. Flyvbjerg A, Landau D, Klien W, Bondy C, Chine E, Raz I, Phillip M, Leroith D. The role of insulin-like growth factors (IGFS) and IGF binding protein in diabetic nephropathy. Proceedings of the 15th International Diabetes Federation. 1995.
3. Raz I, Wexler ID. Extra-renal complications of the type 2 diabetic patient with diabetic nephropathy. In: Nephropathy in Type 2 Diabetes. Ritz, E., Flisher, D. (eds.) London: Oxford University. Publisher Oxford New York Oxford University Press 1999.
4. Guest Editor: Diabetes-inevitable or preventable? Diabetes-Obesity-Metabolism 3: (supl 1)1- 43, 2001.
5. Khamaisi M, Symmer L, Raz I. Thiazolidinediones in cardiovascular risk in type 2 diabetes mellitus. In: Cardiovascular risk in type 2 diabetes: assessment and control. Edited by Nicolae Hancu, Springer-Verlag GmBH, New York ,pp. 193-203, 2002
6. Khamaisi M, Wexler I, Raz I. Cardiovascular disease in type 2 diabetes. In : Diabetes :From Research to Diagnosis and Treatment. Edited by I. Raz, E. Shafir published by M.Dunitz, Taylor and Francis Associates U.K 2002.

#### Editorial Positions:

- Practical Problems in Diabetes (editor-in-chief)
- Internal Medicine Update (deputy editor)
- The Israel Medical Association Journal (deputy editor)
- The International Diabetes Monitor Review Journal (Board of Review Editors)
- The Review of Diabetic Studies